References
- 1. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099-106.
- 2. Munoz-Price LS, Quinn JP. The spread of Klebsiella pneumonia carbapenemases: a tale of strains, plasmids, and transposons. Clin Infect Dis. 2009;49:1739–41.
- 3. Chitnis AS, Caruthers PS, Rao AK, Lamb J, Lurvey R, Beau De Rochars V et al. Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol. 2012;33:984-92.
- 4. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths Attributable to Carbapenem- Resistant Enterobacteriaceae Infections. Emerging Infectious Diseases. 2014; 20: 1170-5.10.3201/eid2007.121004
- 5. Kofteridis DP, Valachis A, Dimopoulou D, Maraki S, Christidou A, Mantadakis E et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: a case-case-control study. J Infect Chemother. 2014;20:293-7.10.1016/j.jiac.2013.11.00724703709
- 6. Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I et al. Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 2013;83:307–13.
- 7. Correa L, Martino MD, Siqueira I, Pasternak J, Gales AC, Silva CV et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis. 2013;13:80.10.1186/1471-2334-13-8023398691
- 8. Ulu AC, Kurtaran B, Inal AS, Kömür S, Kibar F, Çiçekdemir HYet al. Risk Factors of Carbapenem-Resistant Klebsiella pneumoniae Infection: A Serious Threat in ICUs. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2015; 21: 219-24.
- 9. Kiska DL, Gilligan PH. Pseudomonas and Burkholderia. In: Murray PR, Baron EJ, Pfaller MA, et al. (editors). Manual of clinical microbiology. Washington [DC]: American Society for Microbiology; 1995. p. 517-25.
- 10. CLSI: Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Wayne, PA, USA. 2010.
- 11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.10.1111/j.1469-0691.2011.03570.x
- 12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.10.1016/0196-6553(88)90053-3
- 13. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228-36.
- 14. Wu D, Cai J, Liu J. Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae. South Med J. 2011;104:106-10.
- 15. Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents. 2007;30:525-9.
- 16. Borer A, Saidel-Odes L, Eskira S, Nativ R, Riesenberg K, Livshiz-Riven I et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K. pneumoniae. Am J Infect Control. 2012;40:421-25.10.1016/j.ajic.2011.05.022
- 17. Orsi GB, García-Fernández A, Giordano A, Venditti C, Bencardino A, Gianfreda R et al. Risk factors and clinical significance of ertapenem-resistant Klebsi-ella pneumoniae in hospitalised patients. J Hosp Infect. 2011;78:54-8.
- 18. Hu Y, Ping Y, Li L, Xu H, Yan X, Dai H. A retrospective study of risk factors for carbapenem-resistant Klebsi-ella pneumoniae acquisition among ICU patients. J Infect Dev Ctries. 2016;10:208-13.
- 19. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028-33.
- 20. Nathisuwan S, Burgess DS, Lewis JS. Extended-Spectrum -Lactamases: Epidemiology, Detection and Treatment. Pharmacother. 2001;(8):920-8.
- 21. Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect. 2015;70:592-9.
- 22. Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2007;28:1247-54.
- 23. Hudson C, Bent Z, Meagher R, Williams K. Resistance Determinants and Mobile Genetic Elements of an NDM-1-Encoding Klebsiella pneumoniae Strain. PLOS ONE. 2014;9:e99209.
- 24. Bratu S, Brooks S, Burney S, Kochar S, Gupta J, Land-man D et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis. 2007;44:972-5.10.1086/512370
- 25. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:155-64.10.1086/524891